152 related articles for article (PubMed ID: 1592525)
1. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis.
Ceriani RL; Chan CM; Baratta FS; Ozzello L; DeRosa CM; Habif DV
Int J Cancer; 1992 May; 51(3):343-54. PubMed ID: 1592525
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast.
Chan CM; Baratta FS; Ozzello L; Ceriani RL
Breast Cancer Res Treat; 1994; 30(3):243-61. PubMed ID: 7981443
[TBL] [Abstract][Full Text] [Related]
3. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
[TBL] [Abstract][Full Text] [Related]
4. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors.
Xu Y; Kimura N; Yoshida R; Lin H; Yoshinaga K
Oncol Rep; 2001; 8(5):1177-82. PubMed ID: 11496338
[TBL] [Abstract][Full Text] [Related]
6. Multivariate prognostic model for infiltrating ductal carcinoma of the breast in the axillary node-free patient.
Ceriani RL; Baratta F; Gaslonde RJ; De Rosa CM; Ozzello L
Adv Exp Med Biol; 1994; 353():155-67. PubMed ID: 7985534
[No Abstract] [Full Text] [Related]
7. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
8. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
12. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
13. Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size.
Swede H; Moysich KB; Winston JS; Hurd TC; Edge SB; Romero-Gutierrez M; Brooks JS; Michalek AM
Breast J; 2003; 9(2):98-105. PubMed ID: 12603382
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Chia SK; Wykoff CC; Watson PH; Han C; Leek RD; Pastorek J; Gatter KC; Ratcliffe P; Harris AL
J Clin Oncol; 2001 Aug; 19(16):3660-8. PubMed ID: 11504747
[TBL] [Abstract][Full Text] [Related]
17. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
Meyer JS; Province MA
Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
[TBL] [Abstract][Full Text] [Related]
18. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group.
Clark RM; Whelan T; Levine M; Roberts R; Willan A; McCulloch P; Lipa M; Wilkinson RH; Mahoney LJ
J Natl Cancer Inst; 1996 Nov; 88(22):1659-64. PubMed ID: 8931610
[TBL] [Abstract][Full Text] [Related]
20. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
